Suppr超能文献

冠心病治疗中与药物反应性表型改变相关驱动基因的发现

Discovery of Drug-Responsive Phenomic Alteration-Related Driver Genes in the Treatment of Coronary Heart Disease.

作者信息

Guan Shuang, Yu Ya-Nan, Li Bing, Gu Hao, Chen Lin, Wang Nian, Wang Bo, Liu Xi, Liu Jun, Wang Zhong

机构信息

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.

Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.

出版信息

Pharmgenomics Pers Med. 2023 Mar 15;16:201-217. doi: 10.2147/PGPM.S398522. eCollection 2023.

Abstract

BACKGROUND

The Xueyu Zheng (XYZ) phenome is central to coronary heart disease (CHD), but efforts to detect genetic associations in the XYZ phenome have been disappointing.

METHODS

The phenomic alteration-related genes (PARGs) for the XYZ phenome were screened using || > 0.4 and p < 0.05 after treatment with Danhong injection at day 14 and day 30. Then, the driver genes for the Protein-Protein Interaction (PPI) networks of the PARGs established using STRING 11.0 were detected using a personalized network control algorithm (PNC). Finally, the molecular correlations of the driver genes with the XYZ phenome were analyzed with the Gene Ontology (GO) biological processes and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways from a holistic viewpoint.

RESULTS

A total of 525 and 309 PARGs in the XYZ phenome at day 14 and day 30 were identified. These genes were separately enriched in 48 and 35 pathways. Furthermore, five driver genes were detected. These genes were mainly correlated with endoplasmic reticulum stress-mediated apoptosis and autophagy regulation, which could suppress atherosclerosis progression.

CONCLUSION

Our study detected the drug-responsive PARGs of the XYZ phenome in CHD and provides an exemplary strategy to investigate the genetic associations among this common phenome and its component symptoms in patients with CHD.

TRIAL REGISTRATION

ClinicalTrials.gov, NCT01681316; registered on September 7, 2012.

摘要

背景

血瘀证表型组是冠心病的核心,但在血瘀证表型组中检测基因关联的努力一直令人失望。

方法

在第14天和第30天用丹红注射液治疗后,使用||>0.4和p<0.05筛选血瘀证表型组的表型改变相关基因(PARG)。然后,使用个性化网络控制算法(PNC)检测使用STRING 11.0建立的PARG的蛋白质-蛋白质相互作用(PPI)网络的驱动基因。最后,从整体角度用基因本体论(GO)生物学过程和京都基因与基因组百科全书(KEGG)通路分析驱动基因与血瘀证表型组的分子相关性。

结果

在第14天和第30天分别鉴定出525个和309个血瘀证表型组中的PARG。这些基因分别富集在48条和35条通路中。此外,检测到5个驱动基因。这些基因主要与内质网应激介导的细胞凋亡和自噬调节相关,可抑制动脉粥样硬化进展。

结论

我们的研究检测到冠心病中血瘀证表型组的药物反应性PARG,并提供了一种示例性策略,以研究冠心病患者中这种常见表型组与其组成症状之间的基因关联。

试验注册

ClinicalTrials.gov,NCT01681316;于2012年9月7日注册。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d226/10024908/22d5f6cdf9d0/PGPM-16-201-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验